SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and ...

State of New Jersey Common Pension Fund D grew its stake in Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 12.6% in the fourth quarter, according to the company in its most recent Form 13F filing ...

Allworth Financial LP lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,117.4% during ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on February 27, 2025, at 12 p.m ...

Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the ...

The new doors AI and machine learning are opening to scientists undoubtedly will invite weighty ethical and moral questions ...

The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...